Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Atherosclerosis I: Introduction01:30

Atherosclerosis I: Introduction

Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests01:27

Atherosclerosis II: Clinical Manifestations and Diagnostic Tests

Atherosclerosis is a progressive disorder that leads to the thickening and narrowing of arterial walls due to plaque buildup. This condition can cause various symptoms depending on the arteries affected:Coronary Artery Disease (CAD): This condition affects the coronary arteries and may lead to chest pain (angina), shortness of breath (dyspnea), heart attacks, and other heart disease symptoms.Cerebrovascular Disease: This affects blood flow to the brain, causing transient ischemic attacks (TIAs)...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA ends...
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA ends...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Context-dependent regulation of endothelial inflammation and atherosclerosis by endothelial microRNA-33.

Atherosclerosis·2026
Same author

Special issue: Lipid metabolic alterations in cancer: Pathogenic mechanisms, therapies and common pathophysiology with cardiovascular disease.

Seminars in cancer biology·2026
Same author

Emerging role of ceramides and other sphingolipids in atherosclerosis.

Atherosclerosis·2026
Same author

Impaired glycosylation promotes rapid transition to hepatocellular carcinoma in model of diet-induced steatotic liver disease.

The Journal of clinical investigation·2026
Same author

Lipid metabolic alterations in cancer: Common pathophysiology with cardiovascular disease.

Seminars in cancer biology·2026
Same author

Sources of essential lipids for Mycoplasma pneumoniae via P116 to target liver and atherosclerotic lesions.

Nature communications·2025

Related Experiment Video

Updated: May 13, 2026

Single Nuclei Isolation from Coronary Endarterectomy Tissue of Coronary Artery Bypass Graft Patients
09:09

Single Nuclei Isolation from Coronary Endarterectomy Tissue of Coronary Artery Bypass Graft Patients

Published on: April 3, 2026

MicroRNAs and atherosclerosis.

Julio Madrigal-Matute1, Noemi Rotllan, Juan F Aranda

  • 1Department of Medicine, Leon H. Charney Division of Cardiology and the Marc and Ruti Bell Vascular Biology and Disease Program, New York University School of Medicine, New York, NY 10016, USA.

Current Atherosclerosis Reports
|March 21, 2013
PubMed
Summary
This summary is machine-generated.

MicroRNAs (miRNAs) are small RNA molecules regulating gene expression. This review highlights their crucial role in cardiovascular diseases like atherosclerosis, exploring their potential as biomarkers and therapeutic targets.

Related Experiment Videos

Last Updated: May 13, 2026

Single Nuclei Isolation from Coronary Endarterectomy Tissue of Coronary Artery Bypass Graft Patients
09:09

Single Nuclei Isolation from Coronary Endarterectomy Tissue of Coronary Artery Bypass Graft Patients

Published on: April 3, 2026

Area of Science:

  • Molecular Biology
  • Cardiovascular Research
  • Genetics

Background:

  • MicroRNAs (miRNAs) are small non-coding RNA molecules that regulate gene expression post-transcriptionally.
  • Initially recognized for their role in cancer, miRNAs are now understood to be critical in cardiovascular diseases (CVDs), particularly atherosclerosis.
  • These molecules influence key cellular functions in endothelial cells, vascular smooth muscle cells, and macrophages, impacting atherosclerotic plaque development.

Purpose of the Study:

  • To review the significant role of microRNAs (miRNAs) in the pathogenesis of atherosclerosis.
  • To discuss the modulatory effects of miRNAs on cellular pathways involved in cholesterol metabolism and plaque progression.
  • To explore the potential of miRNAs as diagnostic biomarkers and therapeutic targets for cardiovascular diseases.

Main Methods:

  • Literature review focusing on recent findings in miRNA research related to atherosclerosis.
  • Analysis of studies investigating miRNA regulation of endothelial cells, vascular smooth muscle cells, and macrophages.
  • Examination of the interplay between miRNA expression and pathways implicated in plaque development, including lipid metabolism.

Main Results:

  • MiRNAs are key regulators of cellular processes central to atherosclerosis.
  • MiRNA expression is dynamically modulated by stimuli throughout all stages of atherosclerotic disease.
  • MiRNAs influence critical pathways such as cholesterol metabolism, directly impacting plaque formation.

Conclusions:

  • MicroRNAs play a pivotal role in the development and progression of atherosclerosis.
  • MiRNAs represent promising biomarkers for diagnosing and monitoring cardiovascular diseases.
  • Targeting miRNAs offers a potential novel therapeutic strategy for treating atherosclerosis and other CVDs.